California Expands Oversight of Healthcare Transactions: New AB 1415 Regulations Impose Additional Filing and Disclosure Requirements
Author
Paul F. Schmeltzer
California has significantly expanded its oversight of healthcare mergers, acquisitions, investments, and management arrangements through newly effective regulations implementing Assembly Bill 1415 (AB 1415). The regulations, which became effective November 2, 2026, represent a substantial expansion of the state’s healthcare transaction review requirements and will have important implications for private equity investors, physician practices, management services organizations (MSOs), and other healthcare businesses operating in California.
AB 1415, enacted in 2025 and effective January 1, 2026, expanded the categories of entities subject to transaction reporting requirements administered by the Office of Health Care Affordability (OHCA), within the California Department of Health Care Access and Information (HCAI). The implementing regulations establish additional filing thresholds, clarify which transactions require notice, and impose more extensive disclosure obligations on certain private equity groups, hedge funds, MSOs, and other entities that own or control healthcare providers.
Although the regulations do not prohibit private equity investment or healthcare acquisitions, they broaden the circumstances under which transactions must be disclosed to OHCA before closing and potentially subjected to a more extensive cost and market impact review. For healthcare organizations and investors contemplating transactions in California, understanding these requirements early in the transaction process will be important to avoiding unexpected closing delays and additional transaction costs.
California’s Healthcare Transaction Review Framework
California established OHCA through the Health Care Quality and Affordability Act, enacted in 2022, to address rising healthcare costs and promote transparency concerning healthcare market consolidation. Beginning in April 2024, certain healthcare entities became subject to requirements to provide advance notice of material change transactions, including mergers, acquisitions, affiliations, and transfers of control. Covered entities generally must submit notice to OHCA at least 90 days before the anticipated closing date.
OHCA reviews proposed transactions to determine whether they warrant a more comprehensive Cost and Market Impact Review (CMIR), which examines potential effects on healthcare costs, competition, quality, and access to services. Although OHCA generally does not have independent authority to prohibit a transaction solely through the CMIR process, its review can significantly delay closing, and its findings may be shared with other regulatory authorities, including the California Attorney General. AB 1415 builds upon this framework by addressing transactions involving investors and management organizations that may exercise substantial influence over healthcare operations without directly owning a licensed healthcare provider.
Expanded Filing Obligations for Private Equity Groups and Hedge Funds
One of the most consequential changes concerns investments by private equity groups and hedge funds. Under the new regulations, a transaction involving a qualifying healthcare entity or MSO may trigger reporting obligations when a private equity group or hedge fund acquires or holds 10% or more of the entity’s assets, equity, debt, or liabilities as a result of the transaction. The threshold also encompasses certain collective investments by groups of investors. Notably, OHCA initially proposed a 5% threshold but increased it to 10% following public comments.
However, the percentage threshold is not the only consideration. A transaction may also trigger reporting requirements when an investor acquires contractual rights allowing it to exercise significant influence over a covered healthcare entity or MSO, even when its ownership interest is below 10%. Such rights may include authority to appoint or replace management or governing body members, veto significant operational or financial decisions, approve budgets or capital expenditures, influence reimbursement arrangements, or otherwise direct material aspects of the healthcare organization’s operations.
Consequently, minority investments that previously appeared unlikely to trigger reporting obligations may now require closer examination. For example, an investor acquiring a 7% equity interest in a qualifying physician practice—together with broad veto rights over indebtedness, operating budgets, or management decisions—may trigger notice requirements notwithstanding the relatively small equity investment. Parties must therefore evaluate not only ownership percentages but also governance provisions, financing arrangements, management rights, and other contractual mechanisms that confer control. These considerations are particularly relevant to physician practice recapitalizations and investment structures designed to preserve physician ownership while granting substantial financial or operational rights to outside investors.
Management Services Organizations Face Increased Scrutiny
AB 1415 and its implementing regulations also expand oversight of certain MSOs, which frequently provide administrative and operational services to physician practices and other healthcare organizations, including revenue cycle management, contracting support, billing, and other nonclinical functions. Such arrangements are particularly common in California because of the state’s restrictions on the corporate practice of medicine. The expanded requirements are significant because MSOs may exercise substantial economic or operational influence over healthcare providers without directly holding professional licenses or owning the clinical practice.
Under the regulations, certain MSO transactions may require notice when the transaction results in an MSO providing covered management and administrative support services to a healthcare entity meeting the applicable $25 million revenue or asset threshold. Reporting obligations may also arise when an MSO provides such services to two or more providers collectively generating at least $10 million in annual California-derived revenue, or when a transaction transfers control, responsibility, or governance of a healthcare entity.
Importantly, not every company providing administrative services qualifies as an MSO for purposes of the new requirements. The statutory definition focuses on specified management and administrative support functions, including provider rate negotiation and revenue cycle management, and the regulations establish additional organizational and relationship criteria. Accordingly, an independent billing vendor, software provider, or administrative services company should not automatically be presumed subject to the new requirements merely because it provides services to healthcare organizations. Rather, the analysis depends on the services performed, ownership and governance relationships, the healthcare organizations involved, and the structure of the proposed transaction.
For healthcare organizations using MSO structures, both the clinical entity and the management organization may need to be evaluated when assessing transaction reporting obligations. A transaction involving the sale of an MSO, for example, may require OHCA notification even if ownership of the underlying physician practice remains unchanged.
Financial Thresholds and Healthcare Roll-Up Transactions
The expanded filing requirements do not eliminate the financial and operational thresholds applicable to healthcare entities. Under the existing framework, certain healthcare entities are subject to reporting requirements when they have at least $25 million in annual California-derived revenue or California assets. Other transactions may be reportable when a healthcare entity has at least $10 million in annual California-derived revenue or assets and participates in a transaction with a larger covered entity or another qualifying entity. Additional reporting considerations apply to transactions valued at $25 million or more, as well as certain transactions involving providers or integrated delivery systems operating in designated primary care Health Professional Shortage Areas.
These thresholds must be evaluated together rather than independently. A transaction is not automatically reportable merely because it exceeds one dollar amount, and smaller transactions are not necessarily exempt. Certain transactions involving control rights, MSOs, or qualifying healthcare providers may trigger filing obligations even when the purchase price is substantially below $25 million.
The regulations also address successive acquisitions of healthcare businesses. Certain related transactions occurring during the preceding 10 years may be considered together when determining whether applicable reporting thresholds are satisfied. These provisions are particularly relevant to private equity-backed platforms pursuing growth through multiple smaller acquisitions, including physician practice acquisitions and MSO transactions. Investors pursuing these strategies should maintain records of prior acquisitions, affiliations, ownership changes, and management arrangements to evaluate the potential impact on future transactions.
Healthcare Real Estate and Sale-Leaseback Transactions
The regulations also expand oversight of certain healthcare real estate transactions. A transaction may trigger notice requirements when real property used to provide healthcare services is transferred to an entity other than the purchaser of the healthcare business or its direct parent, and the surviving healthcare entity must subsequently lease or pay rent for that property.
This provision is particularly relevant to sale-leaseback transactions involving hospitals, skilled nursing facilities, physician practices, and other healthcare facilities. Such transactions are often used to generate liquidity, finance acquisitions, or separate healthcare operations from real estate ownership. OHCA’s expanded review reflects concerns that changes in healthcare real estate ownership may affect operating costs, financial stability, and the long-term availability of healthcare services. Parties contemplating these arrangements should therefore evaluate whether the proposed structure creates additional reporting obligations, even where ownership of the healthcare operations themselves is not changing.
Expanded Disclosure Requirements and Transaction Timing
The regulations substantially increase the information that parties may be required to provide as part of a material change transaction notice. Depending on the transaction, required disclosures may include organizational charts identifying owners holding interests of 5% or more, information concerning affiliated healthcare businesses, financing arrangements, transaction-related debt, anticipated operational changes, executive compensation arrangements, and financial incentives contingent on closing. Private equity groups and hedge funds may also be required to provide information concerning healthcare entities and MSOs directly or indirectly owned, controlled, or financed by participating asset managers and their funds.
These requirements raise legitimate concerns regarding commercially sensitive information. However, the regulations provide mechanisms for requesting confidential treatment, including protections for certain properly marked transaction agreements, compensation documents, contract rates, valuation materials, and other proprietary information. Parties should identify sensitive documents early and prepare appropriate confidentiality requests before submitting transaction materials to OHCA.
The expanded regulations also have important implications for transaction timelines. Covered parties generally must provide notice at least 90 days before closing. Once a complete notice has been submitted, OHCA generally has 45 days to notify the parties that it will not conduct a CMIR or 60 days to determine that a CMIR is warranted. These periods may be tolled while OHCA awaits requested information or where another governmental or judicial review may affect its determination. Material changes to a proposed transaction may also restart the review periods.
If OHCA determines that a full CMIR is necessary, the review can substantially extend the transaction timeline. Although the regulations provide an expedited review mechanism in limited circumstances, including severe financial distress or threatened reductions in critical healthcare services, expedited treatment should not be assumed to be available for ordinary commercial transactions. Parties should account for these requirements when negotiating closing dates, financing commitments, termination provisions, and regulatory approval conditions.
Practical Considerations for Healthcare Organizations and Investors
Healthcare providers, MSOs, investors, and transaction advisors should assess potential OHCA reporting obligations early, preferably before finalizing transaction structures or executing definitive agreements. This assessment should include applicable financial thresholds, ownership percentages, governance rights, relationships among affiliated entities, and the nature of any management arrangements. Particular attention should be given to minority investments and MSO transactions that may trigger reporting obligations even without a majority ownership transfer.
Parties should also incorporate potential regulatory review into transaction timelines and contractual provisions, including appropriate closing conditions and regulatory cooperation obligations. Organizational charts, financial statements, ownership information, financing arrangements, and relevant governance documents should be assembled in advance to minimize delays. Where sensitive commercial information must be submitted, parties should evaluate available confidentiality protections and prepare the necessary supporting materials.
Conclusion
California’s implementation of AB 1415 represents a significant expansion of state oversight of healthcare transactions, particularly those involving private equity investment, MSOs, physician practice consolidation, and healthcare real estate arrangements. While the regulations do not prohibit these transactions, they increase the importance of careful planning and early regulatory analysis.
For healthcare organizations and investors, the principal concern is not necessarily that a proposed transaction will be disallowed, but that an otherwise commercially viable transaction may encounter additional disclosure obligations, regulatory scrutiny, and closing delays. Evaluating OHCA reporting requirements at the outset, rather than treating them as a final closing consideration, can help preserve transaction flexibility, reduce unnecessary costs, and minimize unexpected regulatory complications.
This publication is intended for general informational purposes only and does not constitute legal advice or a solicitation to provide legal services. The information in this publication is not intended to create, and receipt of it does not constitute, a lawyer-client relationship. Readers should not act upon this information without seeking professional legal counsel. The views and opinions expressed herein represent those of the individual author only and are not necessarily the views of Clark Hill PLC. Although we attempt to ensure that postings on our website are complete, accurate, and up to date, we assume no responsibility for their completeness, accuracy, or timeliness.